Pih11 Out-of-Pocket Health Expenditures Related to Prenatal Care: Evidence From Colombia, 2018

Abstract

The relative risk of imrecoxib was collected from randomized controlled trials. Different sceneries of treatment durations and baseline ages were set in the analysis. Results: Over a 6month treatment duration, compared with no treatment, a higher QALYs gained could be found in imrecoxib (0.30), celecoxib (0.27) and diclofenac (0.20). The cost gained per patient was lowest in diclofenac (＄663.38) while highest in imrecoxib (＄912.28). Imrecoxib was a cost-effective option with the ICER of ＄4309 and ＄2489 versus celecoxib and diclofenac, respectively. A similar result could be found in a 12month and 24-month treatment duration. In Chinese OA patients aged $65 years, the ICER was ＄3856 and ＄2738 for imrecoxib versus celecoxib and diclofenac, respectively, over a 6-month treatment duration. Conclusions: With the gross domestic product/capita in Chinese in 2018 was ＄10407, the imrecoxib can be a costeffective option over different treatment durations in Chinese OA patients.

Substantial Out-of-Pocket Health Expenditure on Prenatal Check-Ups: Estimates from a Sample of Pregnant Women in Cartagena, Colombia

“…Preliminary estimates of this study were presented at Virtual ISPOR conference, May 18-20 of 2020. 34…”